在临床研究之外接受治疗的老年多发性骨髓瘤患者的临床结局:聚焦八十岁以上人群的经验
这项回顾性研究分析了2014至2023年间在Maccabi Healthcare Services确诊的652例≥70岁活动性多发性骨髓瘤患者,比较≥80岁组与70至<80岁组的特征、治疗和结局。≥80岁组合并症更多、接受抗骨髓瘤治疗及三药/四药方案比例更低,中位总生存显著更短(25.9 vs 71.3个月),但至下次治疗时间相似;三药/四药方案与更优的至下次治疗时间和总生存相关,达雷妥尤单抗为基础的治疗在两组均改善至下次治疗时间。
要点
- ≥80岁组Charlson合并症指数≥6者占53%,高于70至<80岁组的23%。
- ≥80岁组中位总生存25.9个月,70至<80岁组为71.3个月。
- 三药/四药方案较高至下次治疗时间(HR 0.61)和总生存(HR 0.63)优于两药方案。
核心结论
- ≥80岁患者合并症更多,对其治疗和生存产生不利影响;达雷妥尤单抗对结局有正面影响,强调需采用个体化方法优化老年多发性骨髓瘤患者的治疗。
研究设计与样本
- 回顾性研究,分析2014至2023年间在Maccabi Healthcare Services医疗记录中确诊的652例≥70岁活动性多发性骨髓瘤患者,比较≥80岁组与70至<80岁组。
主要发现
- ≥80岁组(中位年龄83岁)Charlson合并症指数≥6者占53%,70至<80岁组为23%。
- ≥80岁组接受抗骨髓瘤治疗及三药/四药方案的比例更低。
- 中位随访25个月,≥80岁组中位总生存25.9个月,70至<80岁组为71.3个月;仅在接受治疗的患者中分别为33个月和76.9个月。
- 至下次治疗时间两组相似(17.8 vs 22.1个月)。
- 多因素分析显示,与两药方案相比,三药/四药方案与改善的至下次治疗时间(HR 0.61;P < .001)和总生存(HR 0.63;P < .001)相关;较高的Charlson合并症指数评分和年龄≥80岁预测更差的总生存(HR 1.5;P = .003;HR 2.27;P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With an aging population, multiple myeloma (MM) increasingly affects octogenarians (Octos; age of ≥80 years), yet data on their management and outcomes, particularly if treated outside clinical trials, remain limited. This retrospective study analyzed 652 patients aged ≥70 years, diagnosed with active MM between 2014 and 2023, identified in the Maccabi Healthcare Services medical records. Patient characteristics, treatment, time to next treatment (TTNT), overall survival (OS), and factors influencing outcomes, were compared between Octo and older adults (OL) aged 70 to <80 years. Octo patients (median age, 83 years) had more comorbidities and higher Charlson Comorbidity Index (CCI) scores than OL patients (≥6; 53% vs 23%), leading to lower rates of anti-MM therapy administration and reduced triplet/quadruplet regimen use. Over a median follow-up of 25 months, Octo patients had significantly shorter median OS; 25.9 vs 71.3 months, and 33 vs 76.9 months among treated patients only. TTNT was similar (17.8 vs 22.1 months). Multivariate analysis showed that triplet/quadruplet regimen was associated with improved TTNT (hazard ratio [HR], 0.61; P < .001) and OS (HR, 0.63; P < .001) compared with doublets, whereas higher CCI scores and age of ≥80 years predicted worse OS (HR, 1.5; P = .003; and HR, 2.27; P < .001; respectively). Daratumumab-based therapies enhanced TTNT in both age groups (HR, 0.54; P = .017). In conclusion, higher comorbidities in Octo patients adversely affected their management and survival. However, daratumumab positively influenced outcomes, underscoring the need for tailored approaches to optimize treatment in older patients with MM.
引用
- Shpitzer D, Cohen YC, Shragai T, et al. Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience. Blood Adv. 2025. PMID: 40048737. doi:10.1182/bloodadvances.2025015968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。